![Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0014299920300406-gr4.jpg)
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
![Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0014299920300406-gr1.jpg)
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
![Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action | PNAS Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action | PNAS](https://www.pnas.org/cms/10.1073/pnas.0910180106/asset/e6064003-696e-4d3d-87a9-30e07a35a6e1/assets/graphic/zpq9990900780003.jpeg)
Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action | PNAS
![Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-B978012420118700010X-f10-01-9780124201187.jpg)
Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect
The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](https://nida.nih.gov/sites/default/files/images/valenza_zamarripa_fig_3.gif)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](https://nida.nih.gov/sites/default/files/styles/featured_card/public/images/Jedema_promo.jpg?itok=2V-L7bzP)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cms/10.1126/scisignal.aai8441/asset/236282b7-67c8-485b-87f5-2c5e8c53b95c/assets/graphic/9_ra117_f1.jpeg)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](https://nida.nih.gov/sites/default/files/images/valenza_zamarripa_fig_2.gif)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
![Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study - Journal of Substance Abuse Treatment Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study - Journal of Substance Abuse Treatment](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/8254a6e9-2170-460f-adab-65eb814c3139/gr1.jpg)
Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study - Journal of Substance Abuse Treatment
![A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0031942217300420-fx1.jpg)
A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](https://nida.nih.gov/sites/default/files/images/valenza_zamarripa_fig1.gif)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cms/10.1126/scisignal.aai8441/asset/c4b5daf9-bb92-4d81-a968-9dba715fc066/assets/graphic/9_ra117_f3.jpeg)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
![The atomistic level structure for the activated human κ-opioid receptor bound to the full Gi protein and the MP1104 agonist | PNAS The atomistic level structure for the activated human κ-opioid receptor bound to the full Gi protein and the MP1104 agonist | PNAS](https://www.pnas.org/cms/10.1073/pnas.1910006117/asset/f0a69e0c-75d6-4e8c-953c-be40b148f105/assets/graphic/pnas.1910006117fig04.jpeg)
The atomistic level structure for the activated human κ-opioid receptor bound to the full Gi protein and the MP1104 agonist | PNAS
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](https://nida.nih.gov/sites/default/files/styles/content_image_medium/public/images/valenza_zamarripa_promo.jpg?itok=HRbtRBEw)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
![The Role of Mu-Opioids for Reward and Threat Processing in Humans: Bridging the Gap from Preclinical to Clinical Opioid Drug Studies | SpringerLink The Role of Mu-Opioids for Reward and Threat Processing in Humans: Bridging the Gap from Preclinical to Clinical Opioid Drug Studies | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40429-021-00366-8/MediaObjects/40429_2021_366_Fig1_HTML.png)
The Role of Mu-Opioids for Reward and Threat Processing in Humans: Bridging the Gap from Preclinical to Clinical Opioid Drug Studies | SpringerLink
![G protein signaling–biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists | PNAS G protein signaling–biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists | PNAS](https://www.pnas.org/cms/10.1073/pnas.2102178118/asset/98a67052-dfec-4cf4-8516-e832d52c30d8/assets/images/large/pnas.202102178fig03.jpg)